Caricamento...
Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
Myeloproliferative neoplasms are divided into essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Although ruxolitinib was proven to be effective in reducing symptoms, patients rarely achieve complete molecular remission. Therefore, it is relevant to identify new...
Salvato in:
| Pubblicato in: | J Cell Mol Med |
|---|---|
| Autori principali: | , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7521327/ https://ncbi.nlm.nih.gov/pubmed/32790151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15730 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|